20 citations,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Researchers created a fast, accurate computer program to measure hair loss in alopecia areata patients.
Baricitinib therapy helped many patients with severe alopecia regrow hair after 52 weeks.
April 2021 in “Research Square (Research Square)” Achieving 80% or more scalp hair regrowth is considered a successful treatment for significant hair loss.
January 2024 in “JEADV clinical practice” The study helps doctors use patient images to understand and apply SALT scores for treating severe alopecia areata.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Ritlecitinib significantly improves scalp hair regrowth in alopecia areata patients over time.
13 citations,
February 2019 in “Journal of the American Academy of Dermatology” The document concludes that a new system using the SALT score should replace the current alopecia areata classification for better accuracy in assessing severity and prognosis.
39 citations,
November 2017 in “Journal of The American Academy of Dermatology” The document suggests using standardized methods to track and measure hair loss in alopecia areata, including patient self-assessment and a 50% improvement in specific scores as a treatment goal.
September 2022 in “Journal of Investigative Dermatology” Patient-reported outcomes better reflect the quality of life impact of alopecia areata than traditional severity scores.
238 citations,
November 2016 in “Journal of The American Academy of Dermatology” Tofacitinib is effective and safe for severe hair loss, but full regrowth is less likely after 10 years of hair loss.
222 citations,
September 2016 in “JCI insight” Tofacitinib is safe and effective for severe alopecia areata, but hair loss may return 2 months after stopping treatment.
139 citations,
November 2016 in “Journal of the American Academy of Dermatology” Tofacitinib helped regrow hair in most adolescents with alopecia areata, but more research is needed.
130 citations,
February 2018 in “Journal of Investigative Dermatology” Tofacitinib may help treat severe hair loss, but more research is needed.
124 citations,
October 2019 in “Frontiers in Immunology” Janus kinase inhibitors are promising treatments for autoimmune skin diseases like eczema and psoriasis.
67 citations,
January 2013 in “Indian Journal of Dermatology, Venereology and Leprology” The document concludes that alopecia areata is an autoimmune disease without a definitive cure, but treatments like corticosteroids are commonly used.
66 citations,
June 2021 in “Journal of The American Academy of Dermatology” Baricitinib is effective and safe for treating severe alopecia areata.
66 citations,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
49 citations,
May 2018 in “Journal of the American Academy of Dermatology” Applying 2% tofacitinib cream helped some children with severe hair loss grow back hair.
49 citations,
March 2017 in “Journal of the American Academy of Dermatology” Tofacitinib caused significant hair regrowth in adolescents with alopecia universalis who didn't respond to other treatments.
48 citations,
November 2017 in “Journal of the American Academy of Dermatology” Tofacitinib 2% ointment helped hair regrow in 3 out of 10 patients with alopecia areata, but caused side effects like scalp irritation and raised cholesterol in some.
43 citations,
November 2009 in “Archives of dermatology” Alefacept does not effectively treat severe alopecia areata.
42 citations,
November 2018 in “Archives of dermatological research” Apremilast was not effective in treating moderate-to-severe alopecia areata.
38 citations,
June 2015 in “PubMed” Calcipotriol cream can effectively and safely treat mild-to-moderate patchy hair loss.
36 citations,
December 2021 in “The journal of allergy and clinical immunology/Journal of allergy and clinical immunology/The journal of allergy and clinical immunology” Two drugs, ritlecitinib and brepocitinib, improved scalp hair loss condition markers.
28 citations,
December 2017 in “Journal of Investigative Dermatology Symposium Proceedings” Tofacitinib shows promise for treating severe hair loss in adults and teens, with many experiencing regrowth, but hair loss returns when treatment stops.
28 citations,
April 2017 in “Journal of cosmetic dermatology” Low vitamin D can worsen pediatric alopecia areata.
24 citations,
January 2017 in “Pediatric dermatology” 1% anthralin ointment is effective and safe for treating severe alopecia areata in children.
20 citations,
March 2023 in “American Journal of Clinical Dermatology” Baricitinib improved severe hair loss in adults over 52 weeks and was safe to use.
19 citations,
January 2021 in “Journal of the American Academy of Dermatology” Dupilumab may help children with alopecia areata and atopic dermatitis regrow hair.
17 citations,
January 2019 in “Dermatologic Therapy” Tofacitinib is effective and safe for long-term treatment of severe alopecia areata, with many patients achieving complete hair regrowth.
15 citations,
January 2018 in “Annals of Dermatology” Wigs significantly improve the well-being of people with severe hair loss.